But outsourcing is inevitable since the cost in US has been increasing. The other trend is M&A. All the big pharma are cutting work force but they become leaner and more efficient. Since market demand ( cancer, diabetes, neurodiseases) is still huge, one blockbuster drug will keep the company alive for many years. I am still confident about these US pharmas but there will be fewer big pharmas due to M&A
